ERAS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ERAS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:
1. GuruFocus internally developed valuations of the stock, such as GF valuation.Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.
Based on those aspects listed above, GuruFocus believes the risk assessment of Erasca is: No Data: Cannot be evaluated.
For the Biotechnology subindustry, Erasca's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Erasca's Risk Assessment distribution charts can be found below:
* The bar in red indicates where Erasca's Risk Assessment falls into.
Erasca (NAS:ERAS) Risk Assessment Explanation
Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:
(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.
Thank you for viewing the detailed overview of Erasca's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.
Jonathan E Lim | director, 10 percent owner, officer: See Remarks | 11588 SORRENTO VALLEY ROAD, SUITE 17, SAN DIEGO CA 92121 |
Start Valerie Denise Harding | director | C/O IGNYTA, INC., 11111 FLINTKOTE AVE., SAN DIEGO CA 92121 |
Alexander W. Casdin | director | C/O IGNYTA, INC., 11095 FLINTKOTE AVENUE, SUITE D, SAN DIEGO CA 92121 |
Shannon Morris | officer: Chief Medical Officer | C/O ERASCA, INC., 3115 MERRYFIELD ROW, SUITE 300, SAN DIEGO CA 92121 |
James Arthur Bristol | director | C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451 |
Cormorant Asset Management, Lp | director | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Bihua Chen | director | C/O CORMORANT ASSET MANAGEMENT, LP, 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Global Healthcare Master Fund, Lp | director | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Cormorant Private Healthcare Fund Ii, Lp | director | 200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
Jean I Liu | director | 21823 30TH DRIVE SE, BOTHELL WA 98021 |
Pratik S Multani | director | C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121 |
Julie Hambleton | director | C/O FIVE PRIME THERAPEUTICS, INC., TWO CORPORATE DRIVE, SOUTH SAN FRANCISCO CA 94080 |
Ebun Garner | officer: General Counsel | C/O ALPHATEC HOLDINGS, INC., 2051 PALOMAR AIRPORT ROAD, CARLSBAD CA 92011 |
Lim Conyee T. | 10 percent owner | C/O ERASCA, INC., 10835 ROAD TO THE CURE #140, SAN DIEGO CA 92121 |
Arch Venture Fund X, L.p. | 10 percent owner | 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631 |
From GuruFocus
By sperokesalga sperokesalga • 05-02-2023
By sperokesalga sperokesalga • 06-05-2023
By Value_Insider Value_Insider • 12-09-2022
By Stock market mentor Stock market mentor • 01-04-2023
By sperokesalga sperokesalga • 05-01-2023
By GuruFocus Research GuruFocus Editor • 12-16-2022
By sperokesalga sperokesalga • 05-31-2023
By PurpleRose PurpleRose • 08-23-2022
By Value_Insider Value_Insider • 11-22-2022
By sperokesalga sperokesalga • 05-15-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.